• Price (EUR)23.93
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-5.51%
  • Beta--
Data delayed at least 15 minutes, as of Aug 09 2022 07:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sonic Healthcare Limited is an Australia-based healthcare provider. The Company is engaged in the specialist operations in laboratory medicine / pathology, radiology, general practice medicine, and corporate medical services. The Company's segments include Laboratory, Radiology and Other. The Laboratory segment provides pathology/clinical laboratory services in Australia, New Zealand, the United Kingdom, the United States of America, Germany, Switzerland, and Belgium. The Radiology segment provides diagnostic imaging services in Australia. The Other segment includes medical center operations (IPN), occupational health services (Sonic HealthPlus), and other minor operations. Sonic Clinical Services (SCS) is the primary care division of the Company, which provides a range of health services. The Company's services are provided to medical practitioners, hospitals, community health services, and their collective patients. The Company has more than 100 radiology centers.

  • Revenue in AUD (TTM)9.08bn
  • Net income in AUD1.47bn
  • Incorporated1934
  • Employees38.00k
  • Location
    Sonic Healthcare LtdMacquarie Park, 14 Giffnock AveMACQUARIE 2113AustraliaAUS
  • Phone+61 29855-5444
  • Fax+61 29878-5066
  • Websitehttps://www.sonichealthcare.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SHL:ASX since
ProPath Services LLCDeal completed16 Dec 202116 Dec 2021Deal completed-20.62%--
Data delayed at least 20 minutes, as of Aug 09 2022 07:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.